Progyny (NASDAQ:PGNY) Updates FY 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.520-1.620 for the period, compared to the consensus earnings per share estimate of 1.660. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Progyny also updated its Q1 2025 guidance to 0.440-0.470 EPS.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Truist Financial reiterated a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Barclays reduced their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Canaccord Genuity Group dropped their target price on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. raised their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Progyny currently has an average rating of “Hold” and an average price target of $25.83.

Progyny Stock Down 0.5 %

Shares of Progyny stock traded down $0.12 on Thursday, hitting $22.88. The company’s stock had a trading volume of 2,306,329 shares, compared to its average volume of 1,776,190. The company has a market capitalization of $1.95 billion, a P/E ratio of 39.45, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34. Progyny has a 52-week low of $13.39 and a 52-week high of $38.98. The firm has a fifty day moving average price of $20.34 and a 200-day moving average price of $18.65.

Insider Activity

In related news, Chairman David J. Schlanger acquired 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the purchase, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Anevski bought 209,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.